NASDAQ:FULC Fulcrum Therapeutics (FULC) Stock Forecast, Price & News $3.15 0.00 (0.00%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$3.11▼$3.3550-Day Range$2.26▼$3.8052-Week Range$2.25▼$15.00Volume731,159 shsAverage Volume1.12 million shsMarket Capitalization$194.54 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Fulcrum Therapeutics MarketRank™ ForecastAnalyst RatingHold2.13 Rating ScoreUpside/Downside217.5% Upside$10.00 Price TargetShort InterestHealthy6.38% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 3 Articles This WeekInsider TradingSelling Shares$695 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.82) to ($1.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector271st out of 981 stocksPharmaceutical Preparations Industry115th out of 464 stocks 4.1 Analyst's Opinion Consensus RatingFulcrum Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 2 buy ratings, 5 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Fulcrum Therapeutics has a forecasted upside of 217.5% from its current price of $3.15.Amount of Analyst CoverageFulcrum Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.38% of the outstanding shares of Fulcrum Therapeutics have been sold short.Short Interest Ratio / Days to CoverFulcrum Therapeutics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fulcrum Therapeutics has recently decreased by 17.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldFulcrum Therapeutics does not currently pay a dividend.Dividend GrowthFulcrum Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FULC. Previous Next 2.0 News and Social Media Coverage News SentimentFulcrum Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Fulcrum Therapeutics this week, compared to 3 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fulcrum Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $695.00 in company stock.Percentage Held by InsidersOnly 2.50% of the stock of Fulcrum Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fulcrum Therapeutics are expected to decrease in the coming year, from ($1.82) to ($1.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulcrum Therapeutics is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulcrum Therapeutics is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulcrum Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Fulcrum Therapeutics (NASDAQ:FULC) StockFulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.Read More Receive FULC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FULC Stock News HeadlinesJune 7, 2023 | markets.businessinsider.comFulcrum Therapeutics (FULC) Receives a Hold from Stifel NicolausJune 3, 2023 | benzinga.comFULC INVESTOR NOTICE: ROSEN, TRUSTED NATIONAL...June 7, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 31, 2023 | americanbankingnews.comBrokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $10.00May 30, 2023 | markets.businessinsider.comFulcrum Therapeutics (FULC) Gets a Hold from Stifel NicolausMay 24, 2023 | msn.comFulcrum Therapeutics: FSHD Steadily Advancing In Phase 3, Optionality With SCDMay 20, 2023 | americanbankingnews.comHC Wainwright Comments on Fulcrum Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:FULC)May 20, 2023 | americanbankingnews.comSVB Leerink Analysts Raise Earnings Estimates for Fulcrum Therapeutics, Inc. (NASDAQ:FULC)June 7, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 18, 2023 | americanbankingnews.comShort Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Decreases By 6.6%May 17, 2023 | msn.comHC Wainwright & Co. Maintains Fulcrum Therapeutics (FULC) Neutral RecommendationMay 17, 2023 | msn.comOppenheimer Maintains Fulcrum Therapeutics (FULC) Outperform RecommendationMay 16, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Hold on Fulcrum Therapeutics (FULC)May 16, 2023 | finance.yahoo.comFulcrum Therapeutics First Quarter 2023 Earnings: EPS Beats Expectations, Revenues LagMay 16, 2023 | americanbankingnews.comFulcrum Therapeutics (NASDAQ:FULC) PT Lowered to $5.00 at HC WainwrightMay 16, 2023 | finance.yahoo.comQ1 2023 Fulcrum Therapeutics Inc Earnings CallMay 15, 2023 | finance.yahoo.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023May 15, 2023 | markets.businessinsider.comGoldman Sachs Reaffirms Their Hold Rating on Fulcrum Therapeutics (FULC)May 15, 2023 | seekingalpha.comFulcrum Therapeutics appoints new executive chiefMay 15, 2023 | technews.tmcnet.comOMass Therapeutics Announces Appointment of New Board Chair and Series B ExtensionMay 14, 2023 | markets.businessinsider.comWhat Wall Street expects from Fulcrum Therapeutics's earningsMay 12, 2023 | benzinga.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the FirmMay 12, 2023 | benzinga.comFULC LAWSUIT ALERT: Levi & Korsinsky Notifies Fulcrum Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMay 12, 2023 | msn.comA Preview Of Fulcrum Therapeutics's EarningsMay 10, 2023 | benzinga.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fulcrum Therapeutics, Inc. (FULC)May 10, 2023 | benzinga.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the FirmMay 8, 2023 | finance.yahoo.comFulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ETSee More Headlines FULC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FULC Company Calendar Last Earnings3/09/2023Today6/07/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FULC CUSIPN/A CIK1680581 Webwww.fulcrumtx.com Phone(617) 651-8851FaxN/AEmployees104Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$21.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+217.5%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-109,870,000.00 Net Margins-2,687.81% Pretax Margin-2,687.81% Return on Equity-49.35% Return on Assets-43.70% Debt Debt-to-Equity RatioN/A Current Ratio21.02 Quick Ratio21.02 Sales & Book Value Annual Sales$6.34 million Price / Sales30.69 Cash FlowN/A Price / Cash FlowN/A Book Value$3.82 per share Price / Book0.82Miscellaneous Outstanding Shares61,760,000Free Float60,215,000Market Cap$194.54 million OptionableNot Optionable Beta2.11 Key ExecutivesRobert J. GouldPresident, Chief Executive Officer & DirectorMel HayesChief Operating OfficerMani SundararajanSenior Vice President-Technical OperationsJeffrey W. JacobsChief Scientific OfficerIain FraserChief Medical OfficerKey CompetitorsVerastemNASDAQ:VSTMADC TherapeuticsNYSE:ADCTAC ImmuneNASDAQ:ACIUKinnate BiopharmaNASDAQ:KNTEPDS BiotechnologyNASDAQ:PDSBView All CompetitorsInsiders & InstitutionsProShare Advisors LLCBought 10,347 shares on 5/26/2023Ownership: 0.017%JPMorgan Chase & Co.Bought 5,583 shares on 5/18/2023Ownership: 0.308%Graham Capital Management L.P.Bought 125,626 shares on 5/16/2023Ownership: 0.238%Susquehanna Fundamental Investments LLCSold 43,024 shares on 5/16/2023Ownership: 0.067%Susquehanna International Group LLPSold 2,400 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions FULC Stock - Frequently Asked Questions Should I buy or sell Fulcrum Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last year. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FULC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FULC, but not buy additional shares or sell existing shares. View FULC analyst ratings or view top-rated stocks. What is Fulcrum Therapeutics' stock price forecast for 2023? 8 equities research analysts have issued 12-month price objectives for Fulcrum Therapeutics' stock. Their FULC share price forecasts range from $3.00 to $21.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 217.5% from the stock's current price. View analysts price targets for FULC or view top-rated stocks among Wall Street analysts. How have FULC shares performed in 2023? Fulcrum Therapeutics' stock was trading at $7.28 at the beginning of 2023. Since then, FULC stock has decreased by 56.7% and is now trading at $3.15. View the best growth stocks for 2023 here. Are investors shorting Fulcrum Therapeutics? Fulcrum Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 3,940,000 shares, a decline of 17.6% from the April 30th total of 4,780,000 shares. Based on an average trading volume of 1,220,000 shares, the short-interest ratio is currently 3.2 days. View Fulcrum Therapeutics' Short Interest. When is Fulcrum Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our FULC earnings forecast. How were Fulcrum Therapeutics' earnings last quarter? Fulcrum Therapeutics, Inc. (NASDAQ:FULC) released its earnings results on Thursday, March, 9th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.01. The company earned $0.69 million during the quarter, compared to analysts' expectations of $1.92 million. Fulcrum Therapeutics had a negative net margin of 2,687.81% and a negative trailing twelve-month return on equity of 49.35%. What ETFs hold Fulcrum Therapeutics' stock? ETFs with the largest weight of Fulcrum Therapeutics (NASDAQ:FULC) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).ALPS Medical Breakthroughs ETF (SBIO). What other stocks do shareholders of Fulcrum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fulcrum Therapeutics investors own include VIVUS (VVUS), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Kaleido Biosciences (KLDO), VBI Vaccines (VBIV), Xeris Biopharma (XERS), CymaBay Therapeutics (CBAY), Evelo Biosciences (EVLO) and Akero Therapeutics (AKRO). When did Fulcrum Therapeutics IPO? (FULC) raised $76 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO. What is Fulcrum Therapeutics' stock symbol? Fulcrum Therapeutics trades on the NASDAQ under the ticker symbol "FULC." Who are Fulcrum Therapeutics' major shareholders? Fulcrum Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (9.97%), RTW Investments LP (8.92%), Suvretta Capital Management LLC (8.38%), BlackRock Inc. (6.77%), Cowen AND Company LLC (3.52%) and Geode Capital Management LLC (1.72%). Insiders that own company stock include Christopher Morabito, Curtis Gale Oltmans, Diego Cadavid, Greg Tourangeau, James A Geraghty, Owen B Wallace, Peter G Thomson, Peter G Thomson, Ra Capital Management, LP, Robert J Gould and Robert J Gould. View institutional ownership trends. How do I buy shares of Fulcrum Therapeutics? Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Fulcrum Therapeutics' stock price today? One share of FULC stock can currently be purchased for approximately $3.15. How much money does Fulcrum Therapeutics make? Fulcrum Therapeutics (NASDAQ:FULC) has a market capitalization of $194.54 million and generates $6.34 million in revenue each year. The company earns $-109,870,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. How many employees does Fulcrum Therapeutics have? The company employs 104 workers across the globe. How can I contact Fulcrum Therapeutics? Fulcrum Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.fulcrumtx.com. The company can be reached via phone at (617) 651-8851 or via email at christina.tartaglia@sternir.com. This page (NASDAQ:FULC) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.